Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Coukos

Showing results (181-190 of 355) with videos related to

Pageof 36
Sort By:
Human Gene Therapy|June 18, 2005
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinomaFabian Benencia, Maria C Courreges, José R Conejo-García, et al.
Journal of Nanobiotechnology|April 17, 2015
Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cellsJaleh Barar, Vala Kafil, Mostafa Heidari Majd, et al.
Cell Reports. Medicine|September 1, 2021
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1Julie K Fierle, Matteo Brioschi, Mariastella de Tiani, et al.
Advances in Experimental Medicine and Biology|June 13, 2008
Regulatory T cells: a new frontier in cancer immunotherapyBrian G Barnett, Jens Rüter, Ilona Kryczek, et al.
Nature Medicine|December 25, 2007
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyRonald J Buckanovich, Andrea Facciabene, Sarah Kim, et al.
Nature Protocols|April 5, 2007
Laser-capture microdissectionVirginia Espina, Julia D Wulfkuhle, Valerie S Calvert, et al.
Nature Biomedical Engineering|June 10, 2020
High-throughput automated organoid culture via stem-cell aggregation in microcavity arraysNathalie Brandenberg, Sylke Hoehnel, Fabien Kuttler, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2005
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancerFabian Benencia, Maria C Courrèges, José R Conejo-García, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|June 28, 2024
Reflections on the opportunities and challenges of applying experience-based co-design (EBCD) to phase 1 clinical trials in oncologyNils Graber, Nina Canova, Denise Bryant-Lukosius, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor bindingEvripidis Lanitis, Paris Kosti, Catherine Ronet, et al.
Pageof 36

Showing results (181-190 of 355) with videos related to

Sort By:
Pageof 36
Human Gene Therapy|June 18, 2005
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinomaFabian Benencia, Maria C Courreges, José R Conejo-García, et al.
Journal of Nanobiotechnology|April 17, 2015
Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cellsJaleh Barar, Vala Kafil, Mostafa Heidari Majd, et al.
Cell Reports. Medicine|September 1, 2021
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1Julie K Fierle, Matteo Brioschi, Mariastella de Tiani, et al.
Advances in Experimental Medicine and Biology|June 13, 2008
Regulatory T cells: a new frontier in cancer immunotherapyBrian G Barnett, Jens Rüter, Ilona Kryczek, et al.
Nature Medicine|December 25, 2007
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyRonald J Buckanovich, Andrea Facciabene, Sarah Kim, et al.
Nature Protocols|April 5, 2007
Laser-capture microdissectionVirginia Espina, Julia D Wulfkuhle, Valerie S Calvert, et al.
Nature Biomedical Engineering|June 10, 2020
High-throughput automated organoid culture via stem-cell aggregation in microcavity arraysNathalie Brandenberg, Sylke Hoehnel, Fabien Kuttler, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2005
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancerFabian Benencia, Maria C Courrèges, José R Conejo-García, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|June 28, 2024
Reflections on the opportunities and challenges of applying experience-based co-design (EBCD) to phase 1 clinical trials in oncologyNils Graber, Nina Canova, Denise Bryant-Lukosius, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor bindingEvripidis Lanitis, Paris Kosti, Catherine Ronet, et al.
Pageof 36